189506-90-9

Usage

Uses

Used in Pharmaceutical Development:
(3S,4S)-trans-1-benzyl-4-cyclopropyl-3-pyrrolidinecarboxylic acid is used as a key intermediate in the synthesis of pharmaceuticals. Its unique structure allows it to be a building block for the development of new drugs with potential therapeutic applications.
Used in Medicinal Chemistry Research:
In the field of medicinal chemistry, (3S,4S)-trans-1-benzyl-4-cyclopropyl-3-pyrrolidinecarboxylic acid serves as a valuable compound for studying the structure-activity relationships of bioactive molecules. Its incorporation into various chemical entities can lead to the discovery of novel药物 with improved efficacy and selectivity.
Used in Drug Discovery:
(3S,4S)-trans-1-benzyl-4-cyclopropyl-3-pyrrolidinecarboxylic acid is utilized in drug discovery processes to identify new lead compounds with potential therapeutic properties. Its unique structural features make it a promising candidate for further optimization and development into effective drugs.
Overall, (3S,4S)-trans-1-benzyl-4-cyclopropyl-3-pyrrolidinecarboxylic acid is a versatile chemical entity with significant potential in the pharmaceutical and medicinal chemistry sectors, driving innovation and advancement in drug development and research.

Upstream product

• 189498-32-6 (S)-3-((3S,4S)-1-Benzyl-4-cyclopropyl-pyrrolidine-3-carbonyl)-4-phenyl-oxazolidin-2-one 
• 189498-31-5 3-((E)-3-cyclopropylpropenoyl)-4-(S)-phenyl-2-oxazolidinone 
• 81530-31-6 trans-3-cyclopropyl-2-propenoyl chloride 

Relevant academic research and scientific papers

Synthesis and antimicrobial activity of 4H-4-oxoquinolizine derivatives: Consequences of structural modification at the C-8 position

The antibacterial 4H-4-oxoquinolizines were introduced recently to overcome bacterial resistance to fluoroquinolones. They exhibit potent antibacterial activity against Gram-positive, Gram-negative, and anaerobic organisms and are highly active against some quinolone-resistant bacteria including quinolone-resistant MRSA. Preliminary studies indicated that oxoquinolizines possess distinct activity and toxicity profiles as compared with their parent quinolones. In order to develop a potent antibacterial agent with the desired spectrum of activity, good tolerability, and balanced pharmacokinetic profile, we synthesized and evaluated a series of oxoquinolizines with various substituents at the C-8 position. Most compounds tested in this study demonstrated better activity against Gram-positive bacteria than ciprofloxacin and exhibited good susceptibility against ciprofloxacin- and methicillin-resistant S. aureus. While maintaining potent in vitro activity, several compounds showed improved in vivo efficacy over ABT-719 as indicated by the mouse protection test. As an example, the oral ED50 values for the cis-3-amino-4-methylpiperidine analogue 3ss against S. aureus NCTC 10649M, S. pneumoniae ATCC 6303, and E. coli JUHL were 0.8, 2.0, and 1.4 mg/kg, compared to 3.0, 10.0, and 8.3 mg/kg for ABT-719. The current study revealed that the steric and electronic environment conformation, and absolute stereochemistry of the C-8 group are very important to the antibacterial profiles. Structural modifications of the C-8 group provide a useful means to improve the antibacterial activities, physicochemical properties, and pharmacokinetic profiles. Manipulation of the C-8 group also allows us to generate analogues with the desired spectrum of activity, such as analogues that are selective against respiratory pathogens.

Process for synthesis of chiral cis- and trans-3-amino-4-substituted pyrrolidine compounds

Process for preparation of chiral cis-3,4-substituted pyrrolidine compounds having the formulas STR1 and chiral 3,4-trans-substituted pyrrolidine compounds having the formulas STR2 with the assistance of a stereochemically directing chiral oxazolidinone m